Day: May 8, 2025

HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will participate in the D. Boral Capital Inaugural Global Conference. The conference is being held on May 14, 2025, at The Plaza Hotel, 768 Fifth Avenue, New York, NY 10019. President and Chief Executive Officer Dr. Dolev Rafaeli will be hosting one-on-one meetings on May 14, 2025 from 9:00 AM to 3:00 PM (ET). To register for one-on-one meetings with management at The Plaza Hotel in New York City, interested parties should contact John Perez at jperez@dboralcapital.com. About STRATA Skin Sciences, Inc. STRATA Skin Sciences is a medical technology...

VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, announces that its subsidiary ZenaDrone is testing a new proprietary specialized camera that enables more efficient indoor applications such as inventory and security management, when utilizing IQ Nano drone swarms for commercial and US defense applications. The new camera prototype developed by its Taiwan component manufacturing subsidiary, Spider Vision Sensors, in collaboration with its certified electronics manufacturing partner, Suntek Global, will enable faster and more precise collection of data including multiple bar codes simultaneously...

21Shares AG LEI: 254900UWHMJRRODS3Z64 8 May 2025 Publication of Base Prospectus The following Base Prospectus has been approved by the Financial Conduct Authority and is available for viewing: Base Prospectus dated 8 May 2025 (the “Base Prospectus”) relating to the Exchange Traded Products Programme of 21Shares AG. To view the Base Prospectus in full, please paste the following URL into the address bar of your browser: https://www.21shares.com/en-eu/ir/prospectus A copy of the Base Prospectus will be submitted to the Financial Conduct Authority’s Electronic Submission Service and may shortly be viewed on the National Storage Mechanism at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism Enquiries: ETP@21Shares.com DISCLAIMER – INTENDED ADDRESSEES Please note that the information contained in the Base Prospectus may be...

New funding from Dr. Song augments $3.0 million in funding advances from AlpineBrook Capital in 2025 above and beyond the $5.5 million proceeds and additional $4 million commitments in previously-disclosed AlpineBrook convertible notes. SANTA ANA, Calif., May 08, 2025 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that its Chairman & Chief Executive Officer, Paul Y. Song, M.D., has invested $2.65 million cash, derived from the recent successful sale of another biotech business Dr. Song co-founded, in an effort to accelerate the Company’s Phase 2 clinical trial for Alzheimer’s Disease, reduce Company payables and...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) — StepStone Group Inc. (Nasdaq: STEP) today announced that the Company will release its results for the fourth quarter and fiscal year ended March 31, 2025, after the market closes on Thursday, May 22, 2025. Webcast and Earnings Conference Call Management will host a webcast and conference call on Thursday, May 22, 2025, at 5:00 pm ET to discuss the Company’s results for the fourth quarter and fiscal year ended March 31, 2025. The webcast will be made available on the Shareholders section of the Company’s website at https://shareholders.stepstonegroup.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time to register. A replay will also be available on the shareholders website approximately two hours after the conclusion of the event. To...

Company currently initiating additional trial sites and working with study investigators to enroll participants IMNN-001 is the first and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in women with advanced ovarian cancer Data from Phase 2 OVATION 2 Study are encouraging, with new IMNN-001 data to be highlighted in oral presentation at 2025 ASCO Annual Meeting LAWRENCEVILLE, N.J., May 08, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the first trial site has been initiated for the Company’s Phase 3 pivotal study, called OVATION 3, of its lead candidate IMNN-001 in development for the treatment of women with newly diagnosed advanced ovarian cancer. The first trial site is Washington...

CERRITOS, Calif., May 08, 2025 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (NASDAQ: TOI)(“TOI”), one of the largest value-based oncology groups in the United States, announced today that it has been selected to present an abstract at the upcoming ASCO Annual Meeting further validating cost savings and reduced hospitalizations associated with its unique High-Value Cancer Care (HVCC) model*. The study shares new data supporting prior publications which demonstrate superior outcomes for acute-care patients when enrolled in the TOI HVCC model. “Without compromising on the clinical outcomes for our oncology patients, TOI has again demonstrated the ability to drive down both Emergency Department utilization and hospitalizations by over 50%, while simultaneously driving over $12,000 in cost savings per patient enrolled,” said Yale...